ArticleCureus2025

Early Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Ravulizumab in Acetylcholine Receptor-Positive Generalized Myasthenia Gravis Refractory: A Case Report From Latin America.

Manuel Orellana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.